Search - tctmd.com

Displaying 101 - 120 of 124

Sort: Relevancy | Date

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

Conscious Sedation in TAVR Cuts Costs by 25%, Boosts Patient Satisfaction

News Daily News

Conscious Sedation in TAVR Cuts Costs by 25%, Boosts Patient Satisfaction

April 13, 2017

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

September 29, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

August 01, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Daily News

Cardiac Surgery Risk Prediction with EuroSCORE Improved with Updated, Dynamic Modeling

Michael O'Riordan

March 01, 2016

News Daily News

MVARC Document Offers Template for Mitral Valve Therapeutics Research

July 16, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

News Daily News

CoreValve在高风险患者中的生存益处到2年时依然持续存在

July 07, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.